Compare COUR & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COUR | XERS |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 965.6M |
| IPO Year | 2021 | 2021 |
| Metric | COUR | XERS |
|---|---|---|
| Price | $6.04 | $5.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | ★ $11.07 | $10.43 |
| AVG Volume (30 Days) | ★ 5.0M | 2.1M |
| Earning Date | 05-06-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.22 | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $757,500,000.00 | $49,590,000.00 |
| Revenue This Year | $9.34 | $28.65 |
| Revenue Next Year | $6.60 | $18.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 9.04 | ★ 142.67 |
| 52 Week Low | $5.47 | $3.81 |
| 52 Week High | $13.56 | $10.08 |
| Indicator | COUR | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 26.31 |
| Support Level | $5.47 | $4.30 |
| Resistance Level | $6.38 | $5.49 |
| Average True Range (ATR) | 0.29 | 0.34 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 17.10 | 3.62 |
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through two reporting segments: Consumer and Enterprise. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.